IDEAYA Biosciences, Inc.
IDYA
$30.24
$0.391.31%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 207.83M | -- | -- | 7.00M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 207.83M | -- | -- | 7.00M | -- |
| Cost of Revenue | 82.99M | 74.23M | 70.89M | 140.18M | 57.15M |
| Gross Profit | 124.84M | -74.23M | -70.89M | -133.18M | -57.15M |
| SG&A Expenses | 16.39M | 14.58M | 13.50M | 10.96M | 9.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 99.38M | 88.81M | 84.39M | 151.14M | 66.89M |
| Operating Income | 108.45M | -88.81M | -84.39M | -144.14M | -66.89M |
| Income Before Tax | 119.24M | -77.49M | -72.18M | -130.31M | -51.82M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 119.24M | -77.49M | -72.18M | -130.31M | -51.82M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 119.24M | -77.49M | -72.18M | -130.31M | -51.82M |
| EBIT | 108.45M | -88.81M | -84.39M | -144.14M | -66.89M |
| EBITDA | 109.11M | -88.09M | -83.79M | -143.57M | -66.32M |
| EPS Basic | 1.35 | -0.88 | -0.82 | -1.49 | -0.60 |
| Normalized Basic EPS | 0.84 | -0.55 | -0.51 | -1.10 | -0.38 |
| EPS Diluted | 1.33 | -0.88 | -0.82 | -1.49 | -0.60 |
| Normalized Diluted EPS | 0.83 | -0.55 | -0.51 | -1.10 | -0.38 |
| Average Basic Shares Outstanding | 88.53M | 88.47M | 88.36M | 87.34M | 86.19M |
| Average Diluted Shares Outstanding | 89.69M | 88.47M | 88.36M | 87.34M | 86.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |